Lens opacity AREDS score predicts progression

Article

Researchers using the AREDS lens grading scale have found that long-term clinically relevant outcomes can be predicted by 2-year changes in severity of lens opacities.

Researchers using the Age-Related Eye Disease Study (AREDS) lens grading scale have found that long-term clinically relevant outcomes can be predicted by 2-year changes in severity of lens opacities.

Reporting in Ophthalmology, researchers from the National Eye Institute, National Institutes of Health (US) and contract research organization EMMES Corp. conducted a prospective cohort study within a randomized clinical trial of oral supplements. The study enrolled AREDS participants who were free of late age-related macular

degeneration throughout the study, and whose eyes were phakic at baseline.

The researchers examined 3,466 baseline and annual lens photographs of AREDS participants and graded them for cataract severity. They then collected data on cataract surgery and visual acuity through semiannual clinical examinations. Adjusted Cox proportional hazard models were used to analyse the association of the change in lens opacities at 2 years with the incidence of cataract surgery and visual acuity loss of 2 lines or more at 5 years.

They found that the adjusted hazard ratios (HRs) for association of progression to cataract surgery at 5 years were:

  • 2.77 HR for nuclear cataract increase of 1.0 unit or more at 2 years compared with less than 1.0 unit change

  • 1.91 HR for cortical cataract increase of 5% or more in lens opacity in the central 5 mm of the lens at 2 years compared with less than 5% increase

  • 8.25 HR for posterior subcapsular cataract increase of 5% or more versus less than 5% in the central 5 mm of the lens.

For vision loss of 2 lines or more at 5 years, the HRs were as follows:

  • 1.83 HR for nuclear cataract increase of 1.0 unit or more at 2 years compared with less than 1.0 unit change

  • 1.13 HR for cortical cataract increase of 5% or more in lens opacity in the central 5 mm of the lens at 2 years compared with less than 5% increase

  • 3.05 HR for posterior subcapsular cataract increase of 5% or more versus less than 5% in the central 5 mm of the lens.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
Related Content
© 2025 MJH Life Sciences

All rights reserved.